21416-68-2
Chemical Structure
ICRF-196
- CAS No.: 21416-68-2
- Formula:C12H18N4O4
- Molecular Weight:282.30
IUPAC Name: 4,4'-(butane-2,3-diyl)bis(piperazine-2,6-dione)
InChIKey: OBYGAPWKTPDTAS-UHFFFAOYSA-N
SMILES: CC(N(C1)CC(NC1=O)=O)C(N(C2)CC(NC2=O)=O)C
Biological Activity: ICRF-196 is an racemic mixture of the (S,S)- and (R,R)-isomers of ICRF-193 (HY-118590). ICRF-193 is a DNA Topoisomerase II inhibitor. ICRF-193 can inhibit DNA syntheses and induces apoptosis. ICRF-193 exhibits anti-cancer and anti-inflammation effects. ICRF-193 shows cardioprotective effect against anthracycline toxicity to cardiomyocytes. ICRF-193 can be used for the researches of cancer, infection, inflammation and cardiovascular disease, such as acute promyelocytic leukemia[1][2][3][4][5][6].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ICRF-196 | ICRF-196 is an racemic mixture of the (S,S)- and (R,R)-isomers of ICRF-193 (HY-118590). ICRF-193 is a DNA Topoisomerase II inhibitor. ICRF-193 can inhibit DNA syntheses and induces apoptosis. ICRF-193 exhibits anti-cancer and anti-inflammation effects. ICRF-193 shows cardioprotective effect against anthracycline toxicity to cardiomyocytes. ICRF-193 can be used for the researches of cancer, infection, inflammation and cardiovascular disease, such as acute promyelocytic leukemia. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Nakazawa N, et al. ICRF-193, an anticancer topoisomerase II inhibitor, induces arched telophase spindles that snap, leading to a ploidy increase in fission yeast. Genes Cells. 2016 Sep;21(9):978-93. [Content Brief]
- [2]. Niitsu N, et al. The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia. Exp Hematol. 2002 Nov;30(11):1273-82. [Content Brief]
- [3]. Hossain MS, et al. ICRF-193, a catalytic inhibitor of DNA topoisomerase II, inhibits re-entry into the cell division cycle from quiescent state in mammalian cells. Genes Cells. 2002 Mar;7(3):285-94 [Content Brief]
- [4]. Brindle A, et al. The Bisdioxopiperazine ICRF-193 Attenuates LPS-induced IL-1β Secretion by Macrophages. Inflammation. 2024 Feb;47(1):84-98. [Content Brief]
- [5]. Jirkovská A, et al. Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions. J Med Chem. 2021 Apr 8;64(7):3997-4019. [Content Brief]
- [6]. Tanimoto C, et al. ICRF-193 modifies etoposide-induced apoptosis in thymocytes. Acta Med Okayama. 1995 Dec;49(6):281-6. [Content Brief]
Keywords
